Compare NSAID

7 products »

close Created with Sketch.

Prolensa

Bausch + Lomb Inc.

Prolensa (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

At-a-Glance
  • Mechanism of Action: Bromfenac is a nonsteroidal anti-inflammatory drug that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase (COX) 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
  • Dosage: Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days postsurgery

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Bromfenac sodium sesquihydrate

Application

Topical

Status

Prescription

Strength

0.7%

Company Information

Contact the company for additional information, availability, or pricing:

Bausch + Lomb Inc.

bausch.com

400 Somerset Corporate Blvd.

Bridgewater, NJ 08807